Multiple Myeloma: Determining Prognosis and Choosing Therapy CME/CE

Seema Singhal, MDAuthor Information and Disclosures

Release Date: May 20, 2008; Valid for credit through May 20, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 ANCC contact hours

The content of this activity was developed by NCCN and the presenter. This activity was recorded on April 4, 2008, and is designed to be completed within approximately 30 minutes.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 National Comprehensive Cancer Network
Millennium
Learning Objectives
Following this activity, participants should be able to:
  • Define the role of prognostic modeling in management of multiple myeloma
  • Discuss the rationale for selection of first and subsequent lines of therapy
Author Disclosures
Seema Singhal, MD
Professor of Medicine, Feinberg School of Medicine of Northwestern University; Director, Myeloma Program, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Disclosure: Dr. Singhal has disclosed that she has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in her presentation or who may financially support the educational activity. She has served as a speaker for Celgene Corporation and Millennium Phamaceuticals, Inc.

Dr. Singhal has indicated that her presentation will include discussion of investigational or unlabeled uses of a product.
 
National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.

NCCN designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

This activity is approved for 0.5 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

More Activities from NCCN

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.